(Q37376742)
Statements
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa (English)
Thomas J Conlon
Kirsten Erger
Travis Cossette
Ji-jing Pang
Renee Ryals
Nathalie Clément
Brian Cleaver
Issam McDoom
Shannon E Boye
Marc C Peden
Mark B Sherwood
Corinne R Abernathy